Picture of Ryvu Therapeutics SA logo

RVU Ryvu Therapeutics SA News Story

0.000.00%
pl flag iconLast trade - 00:00
HealthcareSpeculativeSmall CapSucker Stock

Brief: Ryvu Therapeutics Signs EUR 1.2 Mln Deals With Labcourp Drug Development

April 20 (Reuters) - Ryvu Therapeutics SA  RVU.WA :
    * SIGNS DEALS WITH LABCOURP DRUG DEVELOPMENT
    * UNDER DEALS TOTAL COST OF SERVICES PROVIDED ESTIMATED AT
EUR 1.2
MLN
    * SIGNS DEALS FOR START UP OF TWO CLINICAL STUDIES RVU120
PHASE II
IN HEMATOLOGICAL MALIGNANCIES
    * SERVICES COVERED BY AGREEMENTS CONCERN START-UP OF SECOND
AND
THIRD PHASE II CLINICAL TRIALS RVU120, WHICH ARE SCHEDULED TO
START BY END 2023

Source text for Eikon:  ID:nEM9rG4r2a 
Further company coverage:  RVU.WA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))

Recent news on Ryvu Therapeutics SA

See all news